China
Africa
Explore chapters and articles related to this topic
Thiocolchicoside
Published in Anton C. de Groot, Monographs in Contact Allergy, 2021
Thiocolchicoside is a semisynthetic derivative of colchicine, a natural anti-inflammatory glycoside which originates from the flower seeds of Superba gloriosa. It is a muscle relaxant with anti-inflammatory and analgesic effects. Thiocolchicoside is used as an adjuvant drug in the treatment of painful muscle spasms and in acute spinal pathology. Some other conditions that may benefit from this medication are acute and chronic lumbar and sciatic pain, cervicobrachial neuralgia, persistent torticollis, and post-traumatic and post-operative pain. It may be administered orally, parenterally or topically (1).
Efficacy and tolerability of orally administered tramadol/dexketoprofen fixed-dose combination compared to diclofenac/thiocolchicoside in acute low back pain: experience from an Italian, single-centre, observational study
Published in Current Medical Research and Opinion, 2020
Stefano Meloncelli, Marco Divizia, Giorgio Germani
Owing to its pharmacological profile, the oral fixed-dose combination tramadol/dexketoprofen 75/25 mg (TRAM/DKP) may provide pain control in acute exacerbations of LBP and be suitable for mixed types of pain including non-specific LBP where nociceptive and neuropathic mechanisms are involved at both local and central levels21. While some evidence on the clinical efficacy of TRAM/DKP in acute LBP had been reported22, further evaluation is needed. Diclofenac/thiocolchicoside 75/4 mg (DIC/THIO) is an i.m. fixed-dose combination of a NSAID and a muscle-relaxant that has shown an analgesic efficacy greater than that achieved by its monocomponents in patients with moderate-to-severe acute LBP23. The present study was designed to compare the analgesic efficacy and tolerability of TRAM/DKP vs. DIC/THIO in patients with moderate-to-severe acute LBP, namely, lumbar radiculopathy due to disc herniation during a 5-day treatment period.
The relationship between pain and herniation radiology in giant lumbar disc herniation causing severe sciatica: 15 cases
Published in British Journal of Neurosurgery, 2022
The patients were routinely provided with explanatory information about the cause of their pain, the possible consequences of lumbar disc herniation and possible treatment modalities. Afterward, the patients were given intramuscular (IM) non-steroid anti-inflammatory drug, thiocolchicoside and corticosteroids 2–3 times totally if there were no contraindications. Absolute rest was recommended for the first 3 d. The patients were informed about symptoms calling for urgent intervention(s) and weekly follow-up visits were scheduled. In these visits, pain status was assessed and parenteral treatment was repeated or oral (analgesic-myorelaxant) treatment was prescribed. The diagnosis, treatment and follow-up of all patients were conducted by the same physician.
Fentanyl use disorder characterized by unprescribed use of transdermal patches: a case report
Published in Journal of Addictive Diseases, 2022
Cavid Guliyev, Zehra Olcay Tuna, Kültegin Ögel
According to DSM-5, the patient was diagnosed with severe opioid (fentanyl) use disorder as seven of the opioid use disorder criteria were fulfilled. The Clinical Opiate Withdrawal Scale (COWS) value was 22 on the first day of the hospitalization. The patient was started on diazepam 40 mg/day, naproxen/codeine phosphate 1650/240 mg/day and thiocolchicoside 24 mg/day for arthralgia and myalgia, trimethobenzamide HCl 600 mg/day for nausea and quetiapine 300 mg/day for insomnia. He participated in psycho-education sessions, and personal therapeutic interviews were conducted. As the withdrawal symptoms subsided on the third day of hospitalization (COWS score was 17), the medications were tapered off. On the fourth day, when the patient stated that he was ready, the used patches that he had previously been reluctant to take off were removed. As the withdrawal symptoms were resolved completely on the 12th day of hospitalization, diazepam, naproxen + codeine phosphate, thiocolchicoside, and trimethobenzamide HCl were discontinued and oral naltrexone 25 mg/day was initiated as maintenance treatment. Upon the completion of the detoxification treatment on the 16th day of hospitalization, the patient was discharged by prescribing quetiapine 300 mg/day and naltrexone 50 mg/day, and an outpatient control visit was scheduled. Since the patient did not come for two consecutive follow-up visits, he was reached via a phone interview. He stated that he could not attend to follow-ups because of his busy work schedule. As learned from the phone interview, he stopped using naltrexone after two weeks, did not use opioids but consumed 500 ml/day of hard drinks. He was informed about his heavy drinking and encouraged for a hospital visit.